Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.52 |
| ▸ | RORC | P51449 | 10/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327658 | 0.93 | PPARG (0.52) | PPARGPTGESRAB9ANPC1TP53 | |
| SCHEMBL29327775 | 0.86 | PPARG (0.54) | PPARGRORCPTGESRAB9ANPC1 | |
| SCHEMBL29327607 | 0.86 | PPARG (0.55) | PPARGRORCPTGESRAB9ANPC1 | |
| SCHEMBL29327950 | 0.82 | MAPT (0.50) | RORCRAB9ANPC1TP53 | |
| SCHEMBL29327651 | 0.81 | PPARG (0.51) | PPARGRAB9ANPC1TP53 | |
| SCHEMBL29327949 | 0.80 | HDAC6 (0.48) | PPARGRORCRAB9ANPC1TP53 | |
| SCHEMBL29327625 | 0.80 | PPARG (0.60) | PPARGRAB9ANPC1TP53THRB | |
| SCHEMBL29327781 | 0.79 | PPARG (0.54) | PPARGPTGESRAB9ANPC1TP53 | |
| SCHEMBL29327609 | 0.79 | PPARG (0.55) | PPARGPTGESRAB9ANPC1LRRK2 | |
| SCHEMBL29327941 | 0.79 | ATR (0.40) | PPARGRAB9ANPC1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | FLARE THERAPEUTICS INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239760-A1 | PPARG INVERSE AGONISTS AND USES THEREOF | PPARG, PPARA, PPARD | PPARG 1/4885RORC 81/4885PTGES 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.